International Journal of Science and Healthcare Research Vol.5; Issue: 3; July-Sept. 2020 Website: ijshr.com Review Article ISSN: 2455-7587 International Journal of Science and Healthcare Research (www.ijshr.com) 202 Vol.5; Issue: 3; July-September 2020 Polycystic Ovary Syndrome (PCOS): Current and Future Therapy Maged MN 1 , Mohamed MN 2 , Lamia H.Shehata 3 1 Mazahmiya Hospital, Ministry of Health, Kingdom of Saudi Arabia. 2 Department of Ob/Gyn, King Fahd Hospital, Ministry of Health, Kingdom of Saudi Arabia. 3 Department of Surgery, Care National Hospital, Kingdom of Saudi Arabia. Corresponding Author: Maged MN ABSTRACT Polycystic ovary syndrome (PCOS) is a multifaceted condition portrayed by constant anovulation and excess ovarian activity, as opposed to different reasons for anovulation that include ovarian lethargy or essential inadequacy. Ongoing examinations showed that PCOS is related with second rate ceaseless aggravation and that women with PCOS are at expanded danger of non-alcoholic fatty liver disease. The inflammatory and metabolic disturbances related with PCOS are clarified to some extent by the conjunction of insulin resistance and obesity however are additionally filled by the androgen abundance. New bits of knowledge into the guideline of hormones and cytokines in muscle and fat tissue bolster the idea that PCOS is a foundational condition. The therapeutic arrangement ought to be customized to the patient phenotype, complaints, and reproductive desire. Of note, the aromatase inhibitor letrozole is by all accounts more powerful than the reference medicate clomiphene citrate to treat barrenness due to PCOS. Fundamental administration by a multidisciplinary team may help the patients to adhere to lifestyle interventions and in this way lessen body adiposity and recuperate their metabolic and reproductive health. Key words: Polycystic ovary syndrome, PCOS, insulin resistance, infertility, menstrual irregularity INTRODUCTION Polycystic ovary condition (PCOS) is the most widely recognized endocrine issue in women, giving a few potential mixes of signs and manifestations, which may incorporate conceptive, endocrine, and metabolic adjustments. PCOS is portrayed by hypothalamic–pituitary–ovary axis dysfunction and anovulation in any case, dissimilar to different reasons for ovulatory failure that highlight inadequate ovarian follicle development or suppressed gonadotropin secretion (or both), PCOS commonly incorporates androgen overabundance and inconspicuous adjustments (not identified by routine tests) in serum levels of gonadotropins and estrogens. PCOS has the potential for serious outcomes, including expanded hazard for the advancement of endometrial hyperplasia and neoplasia (1). Moreover, extra-conceptive appearances of PCOS incorporate insulin resistance (IR), metabolic syndrome (MS), and low-grade chronic inflammation (2–6). Lately, numerous advances have been made in the under-remaining of pathophysiological components and subsequently in the diagnosis and the management of PCOS. Advances and difficulties in PCOS understanding The Rotterdam Consensus, held mutually by the European and the North American relationship of regenerative medication in 2003, characterized the diagnostic rules of PCOS which remain the most utilized worldwide for both individual analysis and research. It characterized PCOS as the nearness of any two of three highlights: hyperandrogenism (clinical or